A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis

200577 citationsJournal Article

Authors

Dennis Bourdette · Oregon Health & Science University

E.V.J. Edmonds · University of New Mexico

Cassandra Smith · Swedish Medical Center

James D. Bowen · VA Puget Sound Health Care System

Charles R.G. Guttmann · Brigham and Women's Hospital

Zs. Nagy · Brigham and Women's Hospital

Jack H. Simon

Abstract

The trivalent TCR peptide in IFA vaccine represents a significant improvement in immunogenicity over previous TCR peptide vaccines and warrants investigation of its ability to treat MS.

Topics & Keywords

Multiple Sclerosis Research Studies Immunotherapy and Immune Responses T-cell and B-cell Immunology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Multiple Sclerosis Journal

Volume 11, Issue 5, pp. 552-561

DOI: 10.1191/1352458505ms1225oa

Field-Weighted Citation Impact: 2.86